Process for attenuated varicella zoster virus vaccine production
US5607852A · kind A · utility
11Cited by
16References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 5, 1994 |
| Grant date | Mar 4, 1997 |
| Priority date | — |
| Expiry date | Dec 5, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A live, attenuated varicella zoster virus vaccine is produced with enhanced yield of VZV. The new process makes mass production of a live VZV vaccine more practical. In addition, optimized monoloyer cell culture conditions provide a process for maximizing monolayer cell density which is useful for enhancing viral vaccine production. According to this process, cell densities approaching 500,000 cells/cm.sup.2 are routinely achieved in conventional culture vessels.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.